| Autor: |
Boelaert, J. R., De Smedt, Roselyne A., De Baere, Y. A., Godard, Claudine A., Matthys, E. G., Schurgers, M. L., Daneels, R. F., Gordts, B. Z., Van Landuyt, H. W. |
| Zdroj: |
Nephrology Dialysis Transplantation; Apr1989, Vol. 4 Issue 4, p278-281, 4p |
| Abstrakt: |
Mupirocin was used in haemodialysis patients in an attempt to eradicate nasal carriage of and to prevent infection caused by this microorganism. The effectiveness of calcium mupirocin as a 2% nasal ointment OB2 (16 patients for 104 patient-months) was compared to that of placebo (18 patients for 147 patient-months) in a double-blind study. Mupirocin or placebo were applied in both anterior nares thrice daily for 2 weeks and subsequently three times weekly for a total of 9 months. During therapy, was recovered from only 6% of the nasal cultures in the mupirocin group compared to 58% in the placebo group (≤0.01). Only one infection was documented in the mupirocin group compared to six in the placebo group (≤0.05). The strain causing the single infection in the mupirocin group was of a different phage type to that of the original nasal strain. In contrast, at least four of the six strains causing infection in the placebo group were of similar phage type to the original nasal strain. All isolates remained mupirocin sensitive (MIC≤1 mg/l). In conclusion, mupirocin nasal ointment was effective in eradicating nasal carriage of and in preventing infections in patients on haemodialysis. [ABSTRACT FROM PUBLISHER] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
